Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CFO Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $19.98, for a total value of $172,567.26. Following the completion of the sale, the chief financial officer now directly owns 73,849 shares in the company, valued at approximately $1,475,503.02. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Kory James Wentworth also recently made the following trade(s):
- On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The shares were sold at an average price of $14.97, for a total transaction of $47,829.15.
Entrada Therapeutics Price Performance
Shares of Entrada Therapeutics stock traded up $0.17 on Wednesday, reaching $19.96. The company had a trading volume of 219,660 shares, compared to its average volume of 107,128. The firm has a market cap of $746.90 million, a price-to-earnings ratio of 12.58 and a beta of -0.26. The firm’s 50-day moving average price is $16.53 and its two-hundred day moving average price is $15.83. Entrada Therapeutics, Inc. has a 1 year low of $10.75 and a 1 year high of $20.49.
Hedge Funds Weigh In On Entrada Therapeutics
Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new stake in Entrada Therapeutics in the 2nd quarter worth about $636,000. The Manufacturers Life Insurance Company grew its stake in shares of Entrada Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after buying an additional 2,146 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics in the first quarter worth approximately $79,000. Vanguard Group Inc. lifted its stake in shares of Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after acquiring an additional 13,742 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Entrada Therapeutics by 427.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after acquiring an additional 11,965 shares during the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. HC Wainwright increased their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Oppenheimer increased their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th.
Check Out Our Latest Report on TRDA
About Entrada Therapeutics
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Articles
- Five stocks we like better than Entrada Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- Rocket Lab is the Right Stock for the Right Time
- The Risks of Owning Bonds
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- High Flyers: 3 Natural Gas Stocks for March 2022
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.